These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 37294339)

  • 1. How to make the best of NLRP3 inhibitors in patients with COVID-19?
    Kow CS; Ramachandram DS; Hasan SS
    Eur J Clin Pharmacol; 2023 Aug; 79(8):1143-1144. PubMed ID: 37294339
    [No Abstract]   [Full Text] [Related]  

  • 2. Inflammasomes during SARS-CoV-2 infection and development of their corresponding inhibitors.
    Diarimalala RO; Wei Y; Hu D; Hu K
    Front Cell Infect Microbiol; 2023; 13():1218039. PubMed ID: 37360532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological Inhibition of the Nod-Like Receptor Family Pyrin Domain Containing 3 Inflammasome with MCC950.
    Corcoran SE; Halai R; Cooper MA
    Pharmacol Rev; 2021 Jul; 73(3):968-1000. PubMed ID: 34117094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Progress in the relationship between NLRP3 inflammasome and lung injury in COVID-19].
    Ren Z; Che P; Li Z; Mo M; Zhang S; Zhang Y
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2021 Sep; 37(9):844-850. PubMed ID: 34533131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting autophagy regulation in NLRP3 inflammasome-mediated lung inflammation in COVID-19.
    Yong YY; Zhang L; Hu YJ; Wu JM; Yan L; Pan YR; Tang Y; Yu L; Law BY; Yu CL; Zhou J; Li M; Qin DL; Zhou XG; Wu AG
    Clin Immunol; 2022 Nov; 244():109093. PubMed ID: 35944881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The NLRP3 inflammasome and COVID-19: Activation, pathogenesis and therapeutic strategies.
    Zhao N; Di B; Xu LL
    Cytokine Growth Factor Rev; 2021 Oct; 61():2-15. PubMed ID: 34183243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NLRP3, the inflammasome and COVID-19 infection.
    Donnelly SC
    QJM; 2023 Jul; 116(7):477. PubMed ID: 37506510
    [No Abstract]   [Full Text] [Related]  

  • 8. Evaluation of the relationship between serum interleukin-1β levels and expression of inflammasome-related genes in patients with COVID-19.
    Bagheri-Hosseinabadi Z; Shamsizadeh A; Bahrehmand F; Abbasifard M
    BMC Immunol; 2023 Sep; 24(1):30. PubMed ID: 37723427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Posttranslational Regulation of the NLR Family Pyrin Domain-Containing 3 Inflammasome.
    Shim DW; Lee KH
    Front Immunol; 2018; 9():1054. PubMed ID: 29868015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Putative Therapeutic Impact of Inflammasome Inhibitors against COVID-19-Induced ARDS.
    Nabavi SF; Sahebnasagh A; Shahbazi A; Nabavi SM; Azimi S; Kashani MK; Habtemariam S; Rahmani M; Badiee M; Hashemi J; Saghafi F; Amini K; Azimi M; Rezabakhsh A
    Curr Med Chem; 2023; 30(12):1406-1419. PubMed ID: 36065926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of NLRP3 inflammasome in COVID-19 and periodontitis: Possible protective effect of melatonin.
    Şehirli AÖ; Aksoy U; Koca-Ünsal RB; Sayıner S
    Med Hypotheses; 2021 Jun; 151():110588. PubMed ID: 33848919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NLRP3 inflammasome: A joint, potential therapeutic target in management of COVID-19 and fertility problems.
    Bazrafkan M; Hosseini E; Nazari M; Amorim CA; Sadeghi MR
    J Reprod Immunol; 2021 Nov; 148():103427. PubMed ID: 34563758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe COVID-19 patients show a dysregulation of the NLRP3 inflammasome in circulating neutrophils.
    Leal VNC; Andrade MMS; Teixeira FME; Cambui RAG; Roa MEGV; Marra LG; Yamada SM; Alberca RW; Gozzi-Silva SC; Yendo TM; Netto LC; Duarte AJS; Sato MN; Pontillo A
    Scand J Immunol; 2023 Mar; 97(3):e13247. PubMed ID: 36541819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inter-relationships of galectin-3 and NLR family pyrin domain containing 3 inflammasomes with oral lichen planus: a preliminary cross-sectional in vitro study.
    Chen S; Xu X; Liu Y; Yao Y; Yang Y; Meng W
    BMC Oral Health; 2024 Jan; 24(1):14. PubMed ID: 38172822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation and Function of the Nucleotide Binding Domain Leucine-Rich Repeat-Containing Receptor, Pyrin Domain-Containing-3 Inflammasome in Lung Disease.
    Lee S; Suh GY; Ryter SW; Choi AM
    Am J Respir Cell Mol Biol; 2016 Feb; 54(2):151-60. PubMed ID: 26418144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2 infection in severe asthma is associated with worsening of COVID-19 through respiratory NLRP3 inflammasome activation.
    Jeong JS; Choi JY; Kim JS; Park SO; Kim W; Yoon YG; Park HJ; Park KH; Kim DH; Kim JM; Koh GY; Eo SK; Lee YC
    Allergy; 2023 Jan; 78(1):287-290. PubMed ID: 35871401
    [No Abstract]   [Full Text] [Related]  

  • 17. NLRP3 inflammasome activation in COVID-19: an interlink between risk factors and disease severity.
    Amin S; Aktar S; Rahman MM; Chowdhury MMH
    Microbes Infect; 2022 Feb; 24(1):104913. PubMed ID: 34838941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Coronavirus-Induced NLRP3 Inflammasome Activation: A Potential Drug Target in the Treatment of COVID-19.
    Shah A
    Front Immunol; 2020; 11():1021. PubMed ID: 32574259
    [No Abstract]   [Full Text] [Related]  

  • 19. Targeting NLRP3 inflammasome in an animal model for Coronavirus Disease 2019 (COVID-19) caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Sergi CM; Chiu B
    J Med Virol; 2021 Feb; 93(2):669-670. PubMed ID: 32841451
    [No Abstract]   [Full Text] [Related]  

  • 20. NLRP3, the inflammasome and COVID-19 infection.
    Yin M; Marrone L; Peace CG; O'Neill LAJ
    QJM; 2023 Jul; 116(7):502-507. PubMed ID: 36661317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.